Related Experiment Video

Updated: Feb 6, 2026

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

6.0K

Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation

James Stewart1, Angela George1, Susana Banerjee1,2

  • 1a Gynaecology Unit , The Royal Marsden NHS Foundation Trust , London , UK.

Expert Review of Anticancer Therapy
|August 11, 2018
PubMed
Abstract

Insights

Olaparib, a PARP inhibitor, shows promise for treating relapsed BRCA-mutated ovarian cancer. Further research is needed to optimize its use and overcome resistance mechanisms.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Epithelial ovarian cancer frequently relapses, necessitating novel therapeutic targets.
  • BRCA1/BRCA2 mutations impair homologous recombination, a key pathway in DNA repair.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors like olaparib offer a targeted approach.

Purpose of the Study:

  • To review the rationale and efficacy of olaparib in BRCA-mutated relapsed ovarian cancer.
  • To summarize current safety data and ongoing clinical trials for olaparib therapy.
  • To discuss future directions, including resistance mechanisms and combination strategies.

Main Methods:

  • Literature review of studies on olaparib in ovarian cancer.
  • Analysis of clinical trial data regarding efficacy and safety.
  • Discussion of emerging research on treatment resistance and novel therapeutic combinations.

Main Results:

  • Olaparib demonstrates anti-tumor activity in BRCA-mutated ovarian cancer.
  • Existing data support olaparib's efficacy and safety in this patient population.
  • Ongoing Phase III trials are evaluating olaparib's role in various treatment settings.

Conclusions:

  • Olaparib is a valuable therapeutic option for relapsed BRCA-mutated ovarian cancer.
  • Optimal use, including maintenance therapy and combination treatments, is under investigation.
  • Further research is crucial to understand and overcome resistance to PARP inhibitors.
Keywords:
BRCAPARP inhibitorolaparibovarian cancer

More Related Videos

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

34.6K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.5K

Related Concept Videos

Mutations01:39

Mutations

Overview
94.5K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.5K